Spinal and Peripheral Mechanisms Individually Lead to the Development of Remifentanil-induced Hyperalgesia.

Neuroscience

Research Unit for the Neurobiology of Pain, Kyoto Prefectural University of Medicine, Kyoto, Japan; Department of Pain Management and Palliative Care Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan. Electronic address:

Published: October 2020

The present study was performed to determine neuronal loci and individual molecular mechanisms responsible for remifentanil-induced hyperalgesia. The effect of methylnaltrexone (MNX) on remifentanil-induced behavioral hyperalgesia was assessed to distinguish contributions of the peripheral and/or central nervous system to remifentanil-induced hyperalgesia. Phosphorylation of p38 mitogen-activated protein kinase (p38MAPK) in the dorsal root ganglion (DRG) neurons after remifentanil infusion, and the effect of a p38MAPK inhibitor on remifentanil-induced hyperalgesia were analyzed to investigate involvement of p38MAPK in the peripheral mechanisms of remifentanil-induced hyperalgesia. Spinal levels of prodynorphin mRNA after remifentanil infusion, and the effect of the BK2 bradykinin receptor antagonist on remifentanil-induced hyperalgesia were investigated to assess potential spinal mechanisms. The effects of MNX and BK2 antagonists on remifentanil-induced exacerbation of post-incisional hyperalgesia were also investigated using behavioral analysis. Remifentanil infusion induced hyperalgesia in the early (4 h to 2 days) and late (8-14 days) post-infusion periods. MNX inhibited hyperalgesia only during the early post-infusion period. p38MAPK phosphorylation was observed in the DRG neuron, and the p38MAPK inhibitor inhibited hyperalgesia during the early post-infusion period. Prodynorphin expression increased in the spinal cord, and a BK2 antagonist inhibited hyperalgesia during the late post-infusion period. Remifentanil-induced exacerbation of incisional hyperalgesia was inhibited by MNX and the BK2 antagonist. The present study demonstrated that remifentanil activates peripheral and spinal neurons to promote chronologically distinctive hyperalgesia. p38MAPK phosphorylation in the DRG neuron leads to peripherally-driven hyperalgesia during the early post-infusion period, while spinal dynorphin-bradykinin signaling promotes hyperalgesia during the late post-infusion period.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuroscience.2020.08.014DOI Listing

Publication Analysis

Top Keywords

remifentanil-induced hyperalgesia
24
post-infusion period
20
hyperalgesia
16
hyperalgesia early
16
remifentanil infusion
12
inhibited hyperalgesia
12
early post-infusion
12
remifentanil-induced
9
peripheral mechanisms
8
p38mapk inhibitor
8

Similar Publications

Pharmacological interventions for remifentanil-induced hyperalgesia: A systematic review and network meta-analysis of preclinical trials.

PLoS One

December 2024

Institute of Applied Health Sciences, Epidemiology Group, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, United Kingdom.

Background: To improve perioperative pain management, several interventions have been suggested for the prevention of increased pain sensitivity caused by opioids (called opioid-induced hyperalgesia). It is currently unclear which intervention is the most effective or appropriate in preventing opioid-induced hyperalgesia. Remifentanil is the most investigated opioid causing opioid-induced hyperalgesia.

View Article and Find Full Text PDF

Remifentanil-induced inflammation in microglial cells: Activation of the PAK4-mediated NF-κB/NLRP3 pathway and onset of hyperalgesia.

Brain Behav Immun

January 2025

School of Clinical Medicine, Chengdu Medical College, Chengdu 610500, Sichuan Province, China; Department of Anesthesiology, The First Affiliated Hospital of Chengdu Medical College, Chengdu 610500, Sichuan Province, China. Electronic address:

Article Synopsis
  • The study investigates the mechanisms behind hyperalgesia (increased pain sensitivity) that occurs after the use of remifentanil, an opioid used during surgery, focusing on the NF-κB/NLRP3 inflammasome pathway.
  • Researchers established a model of remifentanil-induced hyperalgesia and conducted various tests, including proteomic analysis and measurements of pain thresholds in rats, to explore protein changes and inflammatory responses in the spinal cord.
  • Results showed that remifentanil increases PAK4 protein levels and inflammatory markers in the spinal cord, and using inhibitors for NLRP3 or PAK4 reduced hyperalgesia and inflammation, highlighting potential therapeutic targets for managing postoperative pain.*
View Article and Find Full Text PDF

Navigating the Postoperative Management of Remifentanil-Induced Hyperalgesia: A Case Report.

J Pain Palliat Care Pharmacother

September 2024

PharmD, Department of Pharmacy, Mayo Clinic, Rochester, NY, USA.

Opioid induced hyperalgesia in the postoperative setting presents a significant challenge for clinicians managing postoperative pain in opioid tolerant patients. Remifentanil is a fentanyl analog frequently utilized in anesthesia for its favorable pharmacokinetic profile. However, as described in the case report, it may also increase the risk of postoperative hyperalgesia.

View Article and Find Full Text PDF

Remifentanil-induced hyperalgesia: the current state of affairs.

Curr Opin Anaesthesiol

August 2024

Department of Anesthesiology, Perioperative & Pain Medicine, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, Utah, USA.

Remifentanil-induced hyperalgesia (RIH) is a part of a general opioid-induced hyperalgesia (OIH) syndrome, seemingly resulting from abrupt cessation of continuous remifentanil infusion at rates equal or exceeding 0.3 mcg/kg/min. The intricate mechanisms of its development are still not completely understood.

View Article and Find Full Text PDF

Intraoperative remifentanil administration has been linked to increased postoperative pain sensitivity. Recent studies have identified the involvement of euchromatic histone-lysine N-methyltransferase 2 (Ehmt2/G9a) in neuropathic pain associated with the transcriptional silencing of many potassium ion channel genes. This study investigates whether G9a regulates the potassium sodium-activated channel subfamily T member 1 (Slo2.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!